EMEA publishes guidance on trials in neonates
This article was originally published in SRA
Executive Summary
The complexity of anatomic and functional adaptation processes in neonates means that even subtle variations made through the administration of drugs can impede the smooth transition to extrauterine life, the European Medicines Agency (EMEA) says in new guidance on the development of medicinal products for use in the neonatal period1.